IMMP

Immutep (IMMP)

Immutep Ltd

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:IMMP

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2025/01/06	22 : 00	GlobeNewswire Inc.	Patient Enrolment Completed for INSIGHT-003	NASDAQ:IMMP	Immutep Ltd
2024/12/17	22 : 00	GlobeNewswire Inc.	Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761	NASDAQ:IMMP	Immutep Ltd
2024/12/16	22 : 00	GlobeNewswire Inc.	Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II	NASDAQ:IMMP	Immutep Ltd
2024/12/13	05 : 33	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMMP	Immutep Ltd
2024/12/12	22 : 15	GlobeNewswire Inc.	Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024	NASDAQ:IMMP	Immutep Ltd
2024/12/11	07 : 26	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMMP	Immutep Ltd
2024/12/10	22 : 00	GlobeNewswire Inc.	Immutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer	NASDAQ:IMMP	Immutep Ltd
2024/11/14	22 : 15	GlobeNewswire Inc.	Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer	NASDAQ:IMMP	Immutep Ltd
2024/11/14	22 : 00	GlobeNewswire Inc.	Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting	NASDAQ:IMMP	Immutep Ltd
2024/10/29	21 : 00	GlobeNewswire Inc.	Immutep Quarterly Activities Report Q1 FY25	NASDAQ:IMMP	Immutep Ltd
2024/10/28	21 : 00	GlobeNewswire Inc.	Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024	NASDAQ:IMMP	Immutep Ltd
2024/10/17	21 : 00	GlobeNewswire Inc.	Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial	NASDAQ:IMMP	Immutep Ltd
2024/10/10	21 : 00	GlobeNewswire Inc.	Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit	NASDAQ:IMMP	Immutep Ltd
2024/10/03	21 : 00	GlobeNewswire Inc.	Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer	NASDAQ:IMMP	Immutep Ltd
2024/09/24	21 : 00	GlobeNewswire Inc.	Immutep Receives A$3.6 million R&D Tax Incentive from French Government	NASDAQ:IMMP	Immutep Ltd
2024/09/24	19 : 06	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMMP	Immutep Ltd
2024/09/18	21 : 00	GlobeNewswire Inc.	New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue Sarcoma	NASDAQ:IMMP	Immutep Ltd
2024/09/16	21 : 00	GlobeNewswire Inc.	Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer	NASDAQ:IMMP	Immutep Ltd
2024/09/10	10 : 54	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMMP	Immutep Ltd
2024/08/20	21 : 00	GlobeNewswire Inc.	Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024	NASDAQ:IMMP	Immutep Ltd
2024/08/14	21 : 00	GlobeNewswire Inc.	Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody	NASDAQ:IMMP	Immutep Ltd
2024/08/07	21 : 00	GlobeNewswire Inc.	Immutep to Participate in Upcoming Investor Conferences	NASDAQ:IMMP	Immutep Ltd
2024/07/31	21 : 00	GlobeNewswire Inc.	Immutep Quarterly Activities Report Q4 FY24	NASDAQ:IMMP	Immutep Ltd
2024/07/22	21 : 00	GlobeNewswire Inc.	Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer	NASDAQ:IMMP	Immutep Ltd
2024/07/17	21 : 00	GlobeNewswire Inc.	Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases	NASDAQ:IMMP	Immutep Ltd
2024/07/12	07 : 40	GlobeNewswire Inc.	Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression	NASDAQ:IMMP	Immutep Ltd
2024/07/03	21 : 00	GlobeNewswire Inc.	Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results	NASDAQ:IMMP	Immutep Ltd
2024/06/25	21 : 00	GlobeNewswire Inc.	Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer	NASDAQ:IMMP	Immutep Ltd
2024/06/05	19 : 00	GlobeNewswire Inc.	Immutep successfully completes institutional placement and institutional component of entitlement offer	NASDAQ:IMMP	Immutep Ltd
2024/06/04	20 : 35	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:IMMP	Immutep Ltd